Company: BWAY
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001171843-25-002347
Chunk: 59

Company: Brainsway Ltd.
Filing Date: 2025-04-22
Form: 20-F
Item: Item 5
Chunk 59
---
 a court of law. A failure to obtain sufficient
intellectual property protection in any foreign country could materially and adversely affect our business, results of operations, and
future prospects. Moreover, we may participate in opposition proceedings to determine the validity of our foreign patents or our competitors’
foreign patents, which could result in substantial costs and divert management’s resources and attention. Additionally, due to uncertainty
in patent protection law, we have not filed applications in many countries where significant markets exist.

Changes in patent law and regulations in other countries or jurisdictions or changes in governmental
bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability
to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. For example, in Europe, beginning
June 1, 2023, European applications and patents may be subjected to the jurisdiction of the Unified Patent Court (UPC) for a single pan-European
infringement action or revocation proceeding. European applications will for now have the option in certain circumstances, upon grant
of a patent, of becoming a Unitary Patent that will be subject to the jurisdiction of the UPC. This is a significant change in European
patent practice. As the UPC is a new court system with few decisions rendered, there is little precedent for parties to rely on at the
court, increasing the uncertainty. The UPC may provide our competitors with a new forum to seek to centrally revoke our European patents
if we do not opt our patents out of the UPC where permitted, and allows for the possibility of a competitor to obtain pan-European injunctions
with their own UPC-designated European patents. As a single court system can invalidate a European patent, we, where applicable, may opt
out of the UPC and as such, each European patent would then need to be challenged in each individual country and each infringement action
pursued in each country.

  34  

After the completion of development and registration
of our patents, third parties may still act to manufacture and/or market products that infringe our patent protected rights, and we may
not have adequate resources to enforce our patents. Any such manufacturing and/or marketing of products that infringe our patent rights
may significantly harm our business, results of operations and prospects.

In addition, due to the extensive time needed to
develop, test, and obtain regulatory approval for new indications of Deep TMS, any patents that protect these indications may expire early
during the